Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007276
Filing Date
2025-05-12
Accepted
2025-05-12 09:35:57
Documents
67
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q avbp-20250331x10q.htm   iXBRL 10-Q 1101665
2 EX-10.1 avbp-20250331xex10d1.htm EX-10.1 647383
3 EX-10.3 avbp-20250331xex10d3.htm EX-10.3 32806
4 EX-31.1 avbp-20250331xex31d1.htm EX-31.1 15908
5 EX-31.2 avbp-20250331xex31d2.htm EX-31.2 14910
6 EX-32.1 avbp-20250331xex32d1.htm EX-32.1 7667
7 EX-32.2 avbp-20250331xex32d2.htm EX-32.2 7661
  Complete submission text file 0001558370-25-007276.txt   6076466

Data Files

Seq Description Document Type Size
8 EX-101.SCH avbp-20250331.xsd EX-101.SCH 41408
9 EX-101.CAL avbp-20250331_cal.xml EX-101.CAL 34023
10 EX-101.DEF avbp-20250331_def.xml EX-101.DEF 149945
11 EX-101.LAB avbp-20250331_lab.xml EX-101.LAB 364413
12 EX-101.PRE avbp-20250331_pre.xml EX-101.PRE 269419
70 EXTRACTED XBRL INSTANCE DOCUMENT avbp-20250331x10q_htm.xml XML 809018
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41929 | Film No.: 25932935
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)